Home › Funds › Laurion Capital Management LP › BBOT

Laurion Capital Management LP position in BBOT

BridgeBio Oncology Therapeutic Inc · Health Care

Laurion Capital Management LP reported holding 2,002,701 shares of BBOT (BridgeBio Oncology Therapeutic Inc) in its Q2 2026 13F filing — a position valued at US$15.3M, representing 0.85% of its reported portfolio and ranking #27 among its reported holdings. Laurion Capital Management LP has disclosed BBOT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)2.00M sh
Reported value held$15.26M
Portfolio Weight0.85%
First reportedQ3 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Laurion Capital Management LP's BBOT position evolved

Laurion Capital Management LP first disclosed a stake in BBOT in Q3 2025 at 1,045,800 shares (US$12.1M). The position peaked in Q4 2025 at 1,464,938 shares, worth US$18.3M. Across 4 filings, Laurion Capital Management LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,002,701 shares valued at US$15.3M — an increase of 80,045 shares quarter over quarter.. Notable position changes include a 40% increase in Q4 2025 (shares fell 29% over the following quarter), a 31% increase in Q1 2026 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 1.05M $12.11M New
Q4 2025 1.46M $18.34M Add
Q1 2026 1.92M $17.21M Add
Q2 2026 2.00M $15.26M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBOT and 13F data

BBOT (BridgeBio Oncology Therapeutic Inc) is a Health Care company. 74 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Omega Fund Management, LLC (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBOT

All BBOT fund holders →

FAQ

How long has Laurion Capital Management LP held BBOT?

Laurion Capital Management LP has disclosed BBOT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is Laurion Capital Management LP's current position in BBOT?

As of Q2 2026, Laurion Capital Management LP holds 2.00M shares of BBOT (BridgeBio Oncology Therapeutic Inc), valued at $15.26M, representing 0.85% of its reported portfolio and ranking #27.

Has Laurion Capital Management LP been buying or selling BBOT?

In the latest 13F filing (Q2 2026), Laurion Capital Management LP increased its position in BBOT. The position peaked in Q4 2025 at 1.46M shares.

Which other funds hold BBOT?

Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Omega Fund Management, LLC, among 74 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.